Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
Boehringer Ingelheim
Novartis
Mallinckrodt
QuintilesIMS
Daiichi Sankyo
Argus Health
Cipla
Citi

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Heterocyclic derivatives of (4-phenyl-piperazine-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imi dazoles and 1H-1,2,4-triazoles
Abstract:Novel heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazol es and 1H-1,2,4-triazoles, useful as antifungal and antibacterial agents.
Inventor(s): Heeres; Jan (Vosselaar, BE), Backx; Leo J. J. (Arendonk, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Filing Date:Jan 14, 1981
Application Number:06/224,992
Claims:1. A chemical compound selected from the group consisting of an azole derivative having the formula: ##STR68## and the pharmaceutically acceptable acid addition salts and stereochemically isometric forms thereof, wherein:

Q is a member selected from the group consisting of CH and N;

Ar is a member selected from the group consisting of phenyl, thienyl, halothienyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl; and

the radical Y is a member selected from the group consisting of

a 1H-pyrrol-1-yl radical of the formula ##STR69## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-pyrazol-1-yl radical of the formula ##STR70## wherein R.sup.5, R.sup.6 and R.sup.7 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-imidazol-1-yl radical of the formula ##STR71## wherein R.sup.8 is selected from the group consisting of hydrogen, lower alkyl, mercapto, lower alkylthio and aryl-lower alkylthio, and R.sup.9 and R.sup.10 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-1,2,4-triazol-1-yl radical of the formula ##STR72## wherein either of R.sup.11 and R.sup.12 is selected from the group consisting of hydrogen, hydroxy, mercapto, lower alkylthio and aryl-lower alkylthio, the remaining being selected from the group consisting of hydrogen, lower alkyl and aryl-lower alkyl;

a 4H-1,2,4-triazol-4-yl radical of the formula ##STR73## wherein R.sup.13 is selected from the group consisting of hydrogen, mercapto, hydroxy, lower alkylthio and aryl lower alkylthio, and R.sup.14 is selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-1,2,3,4-tetrazol-1-yl radical of the formula ##STR74## wherein R.sup.17 is selected from the group consisting of hydrogen, mercapto, lower alkyl, aryl and aryl lower alkyl;

wherein said aryl as used in the foregoing definition is selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.

2. A chemical compound selected from the group consisting of cis-1-{4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxo lan-4-ylmethoxy]phenyl}-4-[4-(1H-imidazol-1-yl)phenyl]piperazine and the pharmaceutically accetable acid addition salts and stereochemically isomeric forms thereof.

3. A chemical compound selected from the group consisting of cis-1-{4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4 -ylmethoxy]phenyl}-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

4. A chemical compound selected from the group consisting of cis-1-{4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxo lan-4-ylmethoxy]phenyl}-4-[4-(1H-imidazol-1-yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

5. A chemical compound selected from the group consisting of cis-1-{4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl-methyl)-1,3-diox olan-4-ylmethoxy]phenyl}-4-{4-[3-(methylthio)-1H-1,2,4-triazol-1-yl]phenyl} piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

6. A chemical compound selected from the group consisting of cis-1-{4-[4-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxo lan-4-ylmethoxy]phenyl}-4-[4-(1H-tetrazol-1-yl)phenyl]piperazine and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof.

7. A composition for combatting the growth of a microorganism selected from the group consisting of fungus and bacterium comprising an inert carrier material and as an active ingredient an effective antifungal or antibacterial amount of a compound selected from the group consisting of an azole derivative having the formula ##STR75## and the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein:

Q is a member selected from the group consisting of CH and N;

Ar is a member selected from the group consisting of phenyl, thienyl, halothienyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl; and

the radical Y is a member selected from the group consisting of

a 1H-pyrrol-1-yl radical of the formula ##STR76## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-pyrazol-1-yl radical of the formula ##STR77## wherein R.sup.5, R.sup.6 and R.sup.7 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-imidazol-1-yl radical of the formula ##STR78## wherein R.sup.8 is selected from the group consisting of hydrogen, mercapto, lower alkylthio and aryl lower alkylthio, and R.sup.9 and R.sup.10 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl and aryl lower alkyl;

a 1H-1,2,4-triazol-1-yl radical of the formula ##STR79## wherein either of R.sup.11 and R.sup.12 is selected from the group consisting of hydrogen, hydroxy, mercapto, lower alkylthio and aryl-lower alkylthio, the remaining being selected from the group consisting of hydrogen, lower alkyl and aryl-lower alkyl;

a 4H-1,2,4-triazol-4-yl radical of the formula ##STR80## wherein R.sup.13 is selected from the group consisting of hydrogen, mercapto, hydroxy, lower alkylthio and aryl lower alkylthio, and R.sup.14 is selected from the group consisting of hydrogen, lower alkyl, aryl and arylllower alkyl;

a 1H-1,2,3,4-tetrazol-1-yl radical of the formula ##STR81## wherein R.sup.17 is selected from the group consisting of hydrogen, mercapto, lower alkyl, aryl and aryl lower alkyl;

wherein said aryl as used in the foregoing definition is selected from the group consisting of phenyl and substituted phenyl, said substituted phenyl having from 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
US Army
Boehringer Ingelheim
Dow
Colorcon
AstraZeneca
US Department of Justice
Chinese Patent Office
Argus Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot